Linezolid in the Treatment of Subjects With Nosocomial Pneumonia Proven to be Due to Methicillin-Resistant Staphylococcus Aureus.

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 05 Oct 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Linezolid (Primary) ; Vancomycin
Indications Methicillin-resistant Staphylococcus aureus infections; Nosocomial pneumonia
Focus Therapeutic Use
Acronyms ZEPHYR
Sponsors Pfizer

05 Jun 2017 Results characterizing resistance patterns in baseline methicillin-resistant Staphylococcus aureus (MRSA) isolates (n=427) presented at the ASM Microbe 2017
18 May 2013 Results of the piggybacked economic analysis in the USA presented at the 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
27 Apr 2013 Results of a post-hoc economic analysis in Spain presented at the 23rd European Congress of Clinical Microbiology and Infectious Diseases.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com